2. According to the statistics of western scholars, during 20 10-2020, the FDA (American Food and Drug Administration) approved 440 new drugs, and the clinical research and development time ranged from 5 years to more than 20 years, with an average time of 8.3 years.
3. As far as Afuddin tablets are concerned, it was originally a drug for treating AIDS, and 20 13 entered the clinical trial. After the outbreak of the COVID-19 epidemic, it was screened by a large number of researchers and confirmed as "a promising drug in COVID-19".
2. COVID-19's drug research and development in different routes in China is under way. 1. China is a world leader in drug research and development in COVID-19. According to relevant figures, China ranks first in the world in the number of patent applications and authorized invention patents in COVID-19, accounting for 56% and 70% of the global patents respectively.
2. COVID-19 drugs that have been listed in China are: COVID-19 neutralizing antibody combination therapy drugs, Ambavavir monoclonal antibody injection and Romovel monoclonal antibody injection (approved for marketing in 2002165438), and oral drug, Afuddin tablets (approved for marketing in July 25th, 2022).
3. There are more than 30 COVID-19 drugs in clinical trials in China. These drugs are either old drugs, new drugs (including afudin tablets already on the market), inhibitors or generic drugs.
Three. COVID-19 specific drugs need to be developed according to the variation of COVID-19. Since the outbreak of the epidemic, many mutations have occurred in COVID-19, from mutant α, β and γ to mutant δ, and then to mutant Omicron. In the future, there may be new mutations in COVID-19.
The constant variation of COVID-19 has not only brought great difficulties to our epidemic prevention and control, but also affected the developed COVID-19 vaccine and COVID-19 drugs. In this regard, the listing of specific drugs in COVID-19 is not a short-term thing, and we should fully realize this.